Insider BuySMMT· · June 4, 2026, 10:09 PM UTC
Summit Therapeutics’ co-CEOs both buy SMMT on the same day
Robert Duggan and Mahkam Zanganeh each added shares — a textbook cluster signal.
Robert Duggan and Mahkam Zanganeh, co-chief executives of Summit Therapeutics, each disclosed open-market purchases of SMMT on the same day, joined by COO/CFO Manmeet Soni. Multiple insiders buying the same name in the same window is the cluster signal DEHY weights explicitly — coordinated conviction reads stronger than any single trade.
Reporting insider: DUGGAN ROBERT W · Co-Chief Executive Officer · discretionary, open-market
The filing, structured
| Security | Date | Type | Shares | Price | Owned after | Holding |
|---|---|---|---|---|---|---|
| Common Stock | 2026-06-04 | Open-market purchase | +100K | $14.60 | 25.82M | Indirect |
FAQ
- What insider transaction did Summit Therapeutics Inc. (SMMT) report?
- Robert Duggan and Mahkam Zanganeh, co-chief executives of Summit Therapeutics, each disclosed open-market purchases of SMMT on the same day, joined by COO/CFO Manmeet Soni. Multiple insiders buying the same name in the same window is the cluster signal DEHY weights explicitly — coordinated conviction reads stronger than any single trade.
- Who made the purchase at $SMMT?
- DUGGAN ROBERT W, Co-Chief Executive Officer, is the reporting insider on this Form 4, a purchase of about $1.5M.
- Was the $SMMT trade an open-market transaction or a 10b5-1 plan?
- The trade was a discretionary, open-market transaction — not executed under a pre-arranged 10b5-1 plan.
- What is the DEHY Score for this $SMMT filing?
- This filing scored 61 out of 100 on the DEHY Score, a 0–100 triage signal for how much analyst attention a filing warrants — not a price prediction.
Structured from public SEC data within seconds of filing. The DEHY Score is a 0–100 triage signal, not investment advice or a price prediction. See methodology.